These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18392997)

  • 1. History of regional chemotherapy for cancer of the extremities.
    Ariyan CE; Brady MS
    Int J Hyperthermia; 2008 May; 24(3):185-92. PubMed ID: 18392997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of isolated limb infusion with mild hyperthermia for melanoma.
    Thompson JF; Kam PC
    Int J Hyperthermia; 2008 May; 24(3):219-25. PubMed ID: 18393000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma.
    Kettelhack C; Kraus T; Hupp T; Manner M; Schlag P
    Eur J Surg Oncol; 1990 Aug; 16(4):370-5. PubMed ID: 2379595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma.
    Noorda EM; Takkenberg B; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Hart GA; Kroon BB
    Ann Surg Oncol; 2004 May; 11(5):491-9. PubMed ID: 15078633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
    J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
    Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
    Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of regional melanoma therapy.
    Padsis J; Turley R; Tyler D
    Expert Opin Pharmacother; 2010 Jan; 11(1):79-93. PubMed ID: 20001431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of isolated limb perfusion to manage recurrent malignant melanoma.
    Ma D; Ariyan S
    Clin Plast Surg; 2000 Jul; 27(3):441-50, ix. PubMed ID: 10941564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Locoregional recurrence of melanomas of the extremities after hyperthermic extremity perfusion: is reperfusion of value?].
    Meyer T; Göhl J; Hohenberger W
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1452-4. PubMed ID: 9931909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models.
    Eggermont AM
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1357-70. PubMed ID: 8854755
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.
    Aloia TA; Grubbs E; Onaitis M; Mosca PJ; Cheng TY; Seigler H; Tyler DS
    Arch Surg; 2005 Nov; 140(11):1115-20. PubMed ID: 16301451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated regional therapy for advanced extremity soft tissue sarcomas.
    Deneve JL; Zager JS
    Surg Oncol Clin N Am; 2012 Apr; 21(2):287-99. PubMed ID: 22365520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
    Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
    J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb perfusion: what is the evidence for its use?
    Noorda EM; Vrouenraets BC; Nieweg OE; Van Coevorden F; Kroon BB
    Ann Surg Oncol; 2004 Sep; 11(9):837-45. PubMed ID: 15313738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regional hyperthermic perfusion--therapeutic concept and long term results].
    Göhl J; Hohenberger W
    Langenbecks Arch Chir Suppl Kongressbd; 1992; ():494-501. PubMed ID: 1493314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of regional therapy: isolated limb infusion and other low flow techniques for extremity melanoma.
    Kam PC; Thompson JF
    Surg Oncol Clin N Am; 2008 Oct; 17(4):795-804, ix. PubMed ID: 18722919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.